An amine-based compound and an organic light-emitting device, the amine-based compound being represented by Formula 1 below: ##STR00001##

An amine-based compound and an organic light-emitting device, the amine-based compound being represented by Formula 1 below: ##STR00001##

Eight-membered ring cyclic carbonates having an oxygen or an acylated nitrogen at position 6 were prepared by reaction of precursor diols with ethyl chloroformate. The cyclic carbonates undergo organocatalyzed ring opening polymerization. In one instance, the initial polymer formed comprises a carbonate repeat unit having a Boc-protected nitrogen in the polymer backbone. Deprotecting the nitrogen with acid forms a cationic carbonate repeat unit having a positive charged secondary ammonium nitrogen in the polymer backbone.

Eight-membered ring cyclic carbonates having an oxygen or an acylated nitrogen at position 6 were prepared by reaction of precursor diols with ethyl chloroformate. The cyclic carbonates undergo organocatalyzed ring opening polymerization. In one instance, the initial polymer formed comprises a carbonate repeat unit having a Boc-protected nitrogen in the polymer backbone. Deprotecting the nitrogen with acid forms a cationic carbonate repeat unit having a positive charged secondary ammonium nitrogen in the polymer backbone.

This disclosure relates to GLP-1 agonists of Formula I:

##STR00001##

including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

This disclosure relates to GLP-1 agonists of Formula I:

##STR00001##

including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Disclosed herein are pharmaceutical compositions comprising biosynthetic allosteric mTOR inhibitors that can have improved pharmacology and reduced toxicity. Also disclosed herein are methods of treating a condition or disease by administering biosynthetic allosteric mTOR inhibitors.

The present disclose includes, among other things, compounds of formula (I) that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.

##STR00001##

The present disclose includes, among other things, compounds of formula (I) that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.

##STR00001##

A liquid developer containing a curable insulating liquid, a cationic polymerization initiator, and a toner particle containing a binder resin and carbon black, wherein the carbon black is basic, or wherein the toner particle contains a carbon black dispersing agent, and the carbon black dispersing agent has a dispersing group and an adsorptive group, and the adsorptive group is an amino group.